Share
𝕏 Facebook LinkedIn

A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas.

PAPER pubmed Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2004 Randomized trial Effect: benefit Evidence: High

Abstract

PURPOSE: To compare the efficacy and toxicity between 2 regimens [5 fluorouracil (5-FU), leucovorin and etoposide (ELF) and 5-FU, leucovorin, cisplatin and epirubicin (PELF)] administered as postoperative adjuvant chemotherapy to patients with completely resected advanced gastric cancer. PATIENTS AND METHODS: Between 1998-2002, 78 patients with advanced gastric cancer were randomly assigned to receive 6 cycles of adjuvant ELF or PELF combination chemotherapy after complete surgical tumor resection. Endpoints were disease-free survival (DFS), overall survival and treatment toxicity. RESULTS: ELF was administered to 37 and PELF to 41 patients. Median overall survival was 12.3 months in the ELF group and 17.2 months in the PELF group (p=0.01), respectively. For the ELF group the median DFS was 17 weeks (range 7-160 weeks), while for the PELF group it was 35 weeks (range 12-172 weeks) (p=0.0004). Two-year overall survival was 8% (3 patients) in the ELF group and 24% (10 patients) in the PELF group (p=0.03). Grade 2 hematologic toxicity occurred in 21% (8 patients) in the ELF group and in 22% (9 patients) in the PELF group (p=0.5) and grade 3 in 29% (11 patients) in the ELF group and in 24% (10 patients) in the PELF group (p=0.2). Grade 2 non-hematologic toxicity was seen in 8% (3 patients) in the ELF group and in 17% (7 patients) in the PELF group (p=0.2). Grade 3 non-hematologic toxicity occurred in 29% (11 patients) in the ELF group and in 26.8% (11 patients in the PELF group) (p=0.2). CONCLUSION: PELF combination chemotherapy resulted in DFS and overall survival advantage compared with ELF. No significant differences in hematologic or non-hematologic toxicities between the two groups were registered. PELF is superior to ELF and represents a valid option for the treatment of gastric cancer.

AI evidence extraction

At a glance
Study type
Randomized trial
Effect direction
benefit
Population
Patients with completely resected advanced gastric adenocarcinoma receiving postoperative adjuvant chemotherapy
Sample size
78
Exposure
Evidence strength
High
Confidence: 74% · Peer-reviewed: yes

Main findings

In 78 randomized patients (ELF n=37; PELF n=41), median overall survival was 12.3 months with ELF vs 17.2 months with PELF (p=0.01). Median DFS was 17 weeks with ELF vs 35 weeks with PELF (p=0.0004), and 2-year overall survival was 8% vs 24% (p=0.03). No statistically significant differences in reported grade 2/3 hematologic or non-hematologic toxicities were observed between groups.

Outcomes measured

  • Disease-free survival (DFS)
  • Overall survival
  • Treatment toxicity (hematologic and non-hematologic; grade 2 and grade 3)
View raw extracted JSON
{
    "study_type": "randomized_trial",
    "exposure": {
        "band": null,
        "source": null,
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": null
    },
    "population": "Patients with completely resected advanced gastric adenocarcinoma receiving postoperative adjuvant chemotherapy",
    "sample_size": 78,
    "outcomes": [
        "Disease-free survival (DFS)",
        "Overall survival",
        "Treatment toxicity (hematologic and non-hematologic; grade 2 and grade 3)"
    ],
    "main_findings": "In 78 randomized patients (ELF n=37; PELF n=41), median overall survival was 12.3 months with ELF vs 17.2 months with PELF (p=0.01). Median DFS was 17 weeks with ELF vs 35 weeks with PELF (p=0.0004), and 2-year overall survival was 8% vs 24% (p=0.03). No statistically significant differences in reported grade 2/3 hematologic or non-hematologic toxicities were observed between groups.",
    "effect_direction": "benefit",
    "limitations": [],
    "evidence_strength": "high",
    "confidence": 0.7399999999999999911182158029987476766109466552734375,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "gastric adenocarcinoma",
        "adjuvant chemotherapy",
        "randomized trial",
        "5-fluorouracil",
        "leucovorin",
        "cisplatin",
        "epirubicin",
        "etoposide",
        "overall survival",
        "disease-free survival",
        "toxicity"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.